{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:50:09Z","timestamp":1772016609716,"version":"3.50.1"},"reference-count":126,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.drudis.2023.103581","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T21:16:44Z","timestamp":1680815804000},"page":"103581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Computer-aided drug design in seeking viral capsid modulators"],"prefix":"10.1016","volume":"28","author":[{"given":"Shujie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edeildo Ferreira","family":"da Silva-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-1036","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103581_b0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2796.2007.01910.x","article-title":"The first postmodern pandemic: 25 years of HIV\/ AIDS","volume":"263","author":"Kallings","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.drudis.2023.103581_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024935","article-title":"Viral hepatitis B: clinical and epidemiological characteristics","volume":"4","author":"Burns","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2023.103581_b0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2023.103581_b0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/aid.2019.0063","article-title":"Trends in HIV-1 drug resistance mutations from a U.S. reference laboratory from 2006 to 2017","volume":"35","author":"Kagan","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.drudis.2023.103581_b0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: evolution over two decades","volume":"26","author":"Yuen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2023.103581_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2023.103581_b0035","first-page":"393","article-title":"Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity","volume":"61","author":"ter Hofstede","year":"2003","journal-title":"Neth J Med"},{"key":"10.1016\/j.drudis.2023.103581_b0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.virusres.2014.07.010","article-title":"Roles of HIV-1 capsid in viral replication and immune evasion","volume":"193","author":"Le Sage","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.drudis.2023.103581_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104917","article-title":"Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B","volume":"182","author":"Viswanathan","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103581_b0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/v13020273","article-title":"The HIV-1 capsid: from structural component to key factor for host nuclear invasion","volume":"13","author":"Scoca","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103581_b0060","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","article-title":"Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)","volume":"25","author":"Ren","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0065","doi-asserted-by":"crossref","first-page":"e03830","DOI":"10.7554\/eLife.03830","article-title":"Dominant drug targets suppress the emergence of antiviral resistance","volume":"3","author":"Tanner","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2023.103581_b0070","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1128\/JVI.05006-11","article-title":"Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid","volume":"86","author":"Kortagere","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103581_b0075","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.bbrc.2015.06.077","article-title":"Development of novel hepatitis B virus capsid inhibitor using in silico screening","volume":"463","author":"Hayakawa","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2023.103581_b0080","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/jm050343d","article-title":"Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein","volume":"48","author":"Steindl","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2016.11.026","article-title":"Exploring the binding mechanism of heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics","volume":"137","author":"Tu","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103581_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2018.12.029","article-title":"Molecular mechanisms of tetrahydropyrrolopyrimidines as HBV capsid assembly inhibitors","volume":"663","author":"Song","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2023.103581_b0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acs.jcim.7b00471","article-title":"Identification of factors promoting HBV capsid self-assembly by assembly-promoting antivirals","volume":"58","author":"Rath","year":"2018","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103581_b0100","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1021\/acs.jcim.9b01010","article-title":"Heteroaryldihydropyrimidines alter capsid assembly by adjusting the binding affinity and pattern of the hepatitis B virus core protein","volume":"59","author":"Liu","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103581_b0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/v13040564","article-title":"All-atom MD simulations of the HBV capsid complexed with AT130 reveal secondary and tertiary structural changes and mechanisms of allostery","volume":"13","author":"P\u00e9rez-Segura","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0110","unstructured":"WHO. HIV Fact Sheet. Geneva; WHO, 2022."},{"key":"10.1016\/j.drudis.2023.103581_b0115","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2023.103581_b0120","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","article-title":"X-ray structures of the hexameric building block of the HIV capsid","volume":"137","author":"Pornillos","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103581_b0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrmicro3503","article-title":"HIV-1 capsid: the multifaceted key player in HIV-1 infection","volume":"13","author":"Campbell","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2023.103581_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.652486","article-title":"HIV-1 capsid core: a bullet to the heart of the target cell","volume":"12","author":"Toccafondi","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2023.103581_b0135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103581_b0140","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/AAC.02574-15","article-title":"Ebselen, a small-molecule capsid inhibitor of HIV-1 replication","volume":"60","author":"Thenin-Houssier","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103581_b0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/acs.jmedchem.5b01089","article-title":"Specific inhibitors of HIV capsid assembly binding to the C-terminal domain of the capsid protein: evaluation of 2-arylquinazolines as potential antiviral compounds","volume":"59","author":"Machara","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0150","doi-asserted-by":"crossref","first-page":"e1001220","DOI":"10.1371\/journal.ppat.1001220","article-title":"HIV capsid is a tractable target for small molecule therapeutic intervention","volume":"6","author":"Blair","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103581_b0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/JVI.01406-10","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization","volume":"85","author":"Shi","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103581_b0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103581_b0165","unstructured":"WHO. HBV Fact Sheet. Geneva; WHO, 2020."},{"key":"10.1016\/j.drudis.2023.103581_b0170","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103581_b0175","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2023.103581_b0180","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1021\/bi0261645","article-title":"Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids","volume":"41","author":"Ceres","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2023.103581_b0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.06.016","article-title":"Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"144","author":"Berke","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103581_b0190","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/jac\/dkaa179","article-title":"Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"75","author":"Verbinnen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2023.103581_b0195","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/acs.jmedchem.7b01914","article-title":"3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (HEC72702), a novel hepatitis B virus capsid inhibitor based on clinical candidate GLS4","volume":"61","author":"Ren","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1021\/acsmedchemlett.9b00550","article-title":"Discovery of a new sulfonamide hepatitis B capsid assembly modulator","volume":"11","author":"Na","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103581_b0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103581_b0210","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/acschembio.0c00320","article-title":"Local stabilization of subunit-subunit contacts causes global destabilization of hepatitis B virus capsids","volume":"15","author":"Schlicksup","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0215","doi-asserted-by":"crossref","first-page":"e31473","DOI":"10.7554\/eLife.31473","article-title":"Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids","volume":"7","author":"Schlicksup","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2023.103581_b0220","doi-asserted-by":"crossref","first-page":"e1006658","DOI":"10.1371\/journal.ppat.1006658","article-title":"HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways","volume":"13","author":"Guo","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103581_b0225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2023.103581_b0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.coviro.2012.03.008","article-title":"Pathogenesis of rhinovirus infection","volume":"2","author":"Kennedy","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2023.103581_b0235","doi-asserted-by":"crossref","first-page":"13562","DOI":"10.1073\/pnas.0804181105","article-title":"Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1\/2 cytokine and IL-10 production","volume":"105","author":"Message","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103581_b0240","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/v13091784","article-title":"Rhinovirus inhibitors: including a new target, the viral RNA","volume":"13","author":"Real-Hohn","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0245","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)63732-9","article-title":"The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance","volume":"264","author":"Rossmann","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0250","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/JVI.78.7.3663-3674.2004","article-title":"VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds","volume":"78","author":"Ledford","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103581_b0255","doi-asserted-by":"crossref","first-page":"14730","DOI":"10.1073\/pnas.96.26.14730","article-title":"Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16","volume":"96","author":"Hadfield","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103581_b0260","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/ijms11083016","article-title":"Advances and challenges in protein-ligand docking","volume":"11","author":"Huang","year":"2010","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103581_b0265","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/ci400040d","article-title":"Docking challenge: protein sampling and molecular docking performance","volume":"53","author":"Elokely","year":"2013","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103581_b0270","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/molecules23081899","article-title":"Binding affinity via docking: fact and fiction","volume":"23","author":"Pantsar","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2023.103581_b0275","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2023.103581_b0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1011115820450","article-title":"DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases","volume":"15","author":"Ewing","year":"2001","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.drudis.2023.103581_b0285","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0290","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/ci200515g","article-title":"Molecular docking using the molecular lipophilicity potential as hydrophobic descriptor: impact on GOLD docking performance","volume":"52","author":"Nurisso","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103581_b0295","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8","article-title":"Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking","volume":"37","author":"Kramer","year":"1999","journal-title":"Proteins"},{"key":"10.1016\/j.drudis.2023.103581_b0300","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10822-012-9547-0","article-title":"Docking and scoring with ICM: the benchmarking results and strategies for improvement","volume":"26","author":"Neves","year":"2012","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.drudis.2023.103581_b0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bmc.2010.11.045","article-title":"Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid","volume":"19","author":"Curreli","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0310","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103581_b0315","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbagen.2014.10.019","article-title":"Enhanced sampling techniques in molecular dynamics simulations of biological systems","volume":"1850","author":"Bernardi","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2023.103581_b0320","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2023.103581_b0325","first-page":"1552","article-title":"Molecular dynamics with helical periodic boundary conditions","volume":"35","author":"Kessler","year":"2014","journal-title":"J Comput Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0330","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins"},{"key":"10.1016\/j.drudis.2023.103581_b0335","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.drudis.2023.103581_b0340","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1021\/ct300156h","article-title":"New interaction parameters for charged amino acid side chains in the GROMOS force field","volume":"8","author":"Reif","year":"2012","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.drudis.2023.103581_b0345","doi-asserted-by":"crossref","DOI":"10.1021\/ct400340s","article-title":"Improving the efficiency of free energy calculations in the Amber molecular dynamics package","volume":"9","author":"Kaus","year":"2013","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.drudis.2023.103581_b0350","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0355","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.drudis.2023.103581_b0360","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1351\/pac199870051129","article-title":"Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Article","volume":"70","author":"Wermuth","year":"1998","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0365","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/17460441.2013.767795","article-title":"Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery","volume":"8","author":"Shin","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2023.103581_b0370","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: challenges and recent advances","volume":"15","author":"Yang","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103581_b0375","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2174\/092986708784049630","article-title":"Pharmacophore-based virtual screening","volume":"15","author":"Sun","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0380","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nature03197","article-title":"Virtual screening of chemical libraries","volume":"432","author":"Shoichet","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103581_b0385","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17460441.2013.761204","article-title":"How far can virtual screening take us in drug discovery?","volume":"8","author":"Kar","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2023.103581_b0390","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17460441.2019.1604677","article-title":"The compromise of virtual screening and its impact on drug discovery","volume":"14","author":"Slater","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2023.103581_b0395","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.drudis.2011.02.011","article-title":"State-of-the-art in ligand-based virtual screening","volume":"16","author":"Ripphausen","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103581_b0400","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","article-title":"Virtual screening techniques in drug discovery: review and recent applications","volume":"19","author":"da Silva Rocha","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0405","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd2615","article-title":"Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening","volume":"7","author":"Tanrikulu","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103581_b0410","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/156802610790232260","article-title":"3D-QSAR in drug design\u2013a review","volume":"10","author":"Verma","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0415","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1021\/ja00226a005","article-title":"Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins","volume":"110","author":"Cramer","year":"1988","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2023.103581_b0420","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1021\/jm981062r","volume":"42","author":"B\u00f6hm","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0425","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A peptide inhibitor of HIV-1 assembly in vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0430","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmb.2008.02.066","article-title":"A cell-penetrating helical peptide as a potential HIV-1 inhibitor","volume":"378","author":"Zhang","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0435","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nsmb967","article-title":"The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor","volume":"12","author":"Ternois","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0440","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/biom11020208","article-title":"Small-molecule anti-HIV-1 agents based on HIV-1 capsid proteins","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2023.103581_b0445","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1039\/D2RA06837K","article-title":"Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins","volume":"13","author":"Kobayakawa","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.drudis.2023.103581_b0450","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-2836(03)00289-4","article-title":"Antiviral inhibition of the HIV-1 capsid protein","volume":"327","author":"Tang","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0455","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmb.2007.07.070","article-title":"Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein","volume":"373","author":"Kelly","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0460","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.1038\/s41598-019-46082-2","article-title":"Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition","volume":"9","author":"Amano","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103581_b0465","doi-asserted-by":"crossref","first-page":"e0103921","DOI":"10.1128\/AAC.01039-21","article-title":"A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid","volume":"65","author":"Chia","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103581_b0470","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bmcl.2015.12.087","article-title":"Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer","volume":"26","author":"Xu","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103581_b0475","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10822-022-00446-5","article-title":"Structure-based virtual screening workflow to identify antivirals targeting HIV-1 capsid","volume":"36","author":"Sun","year":"2022","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.drudis.2023.103581_b0480","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1248\/cpb.c16-00132","article-title":"Molecular dynamics simulations to determine the structure and dynamics of hepatitis B virus capsid bound to a novel anti-viral drug","volume":"64","author":"Watanabe","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.drudis.2023.103581_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2019.197677","article-title":"Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly","volume":"271","author":"Toyama","year":"2019","journal-title":"Virus Res"},{"key":"10.1016\/j.drudis.2023.103581_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116096","article-title":"Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays","volume":"36","author":"Wang","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0495","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/v13050770","article-title":"Discovery of new small molecule hits as hepatitis B virus capsid assembly modulators: structure and pharmacophore-based approaches","volume":"13","author":"Senaweera","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0500","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/v14020348","article-title":"Structure-based discovery of N-sulfonylpiperidine-3-carboxamides as novel capsid assembly modulators for potent inhibition of HBV replication","volume":"14","author":"Yang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0505","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/jm701494b","article-title":"Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein","volume":"51","author":"Rollinger","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0510","first-page":"1070","article-title":"Exploring modifications of an HIV-1 capsid inhibitor: design, synthesis, and mechanism of action","volume":"5","author":"Xu","year":"2018","journal-title":"J Drug Des Res"},{"key":"10.1016\/j.drudis.2023.103581_b0515","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1021\/acs.jmedchem.0c01810","article-title":"Rapid optimization of the metabolic stability of a human immunodeficiency virus type-1 capsid inhibitor using a multistep computational workflow","volume":"64","author":"Meuser","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0520","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/acsmedchemlett.7b00288","article-title":"Design, synthesis, and evaluation of tetrahydropyrrolopyrimidines as capsid assembly inhibitors for HBV treatment","volume":"8","author":"Li","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103581_b0525","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2016.02.012","article-title":"Recent advances in coarse-grained modeling of virus assembly","volume":"18","author":"Hagan","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2023.103581_b0530","doi-asserted-by":"crossref","first-page":"11568","DOI":"10.1038\/ncomms11568","article-title":"Coarse-grained simulation reveals key features of HIV-1 capsid self-assembly","volume":"7","author":"Grime","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103581_b0535","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1021\/jacs.9b01413","article-title":"Off-Pathway assembly: a broad-spectrum mechanism of action for drugs that undermine controlled HIV-1 viral capsid formation","volume":"141","author":"Pak","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2023.103581_b0540","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1021\/acs.jmedchem.1c02040","article-title":"The mechanism of action of hepatitis B virus capsid assembly modulators can be predicted from binding to early assembly intermediates","volume":"65","author":"Pavlova","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0545","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/v13050920","article-title":"Molecular dynamics free energy simulations reveal the mechanism for the antiviral resistance of the M66I HIV-1 capsid mutation","volume":"13","author":"Sun","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103581_b0550","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1513803112","article-title":"High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein","volume":"112","author":"Klumpp","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103581_b0555","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/acs.jmedchem.7b00083","article-title":"Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors","volume":"60","author":"Qiu","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0560","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1021\/acs.jmedchem.8b00654","article-title":"Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)","volume":"61","author":"Vandyck","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0565","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1021\/acs.jmedchem.0c00015","article-title":"Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities","volume":"63","author":"Sun","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113780","article-title":"Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors","volume":"225","author":"Ma","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103581_b0575","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01686-19","article-title":"A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers","volume":"64","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103581_b0580","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.1222379110","article-title":"Structure of human enterovirus 71 in complex with a capsid-binding inhibitor","volume":"110","author":"Plevka","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103581_b0585","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/ijms20163870","article-title":"Structural and functional properties of the capsid protein of Dengue and related flavivirus","volume":"20","author":"Faustino","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103581_b0590","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41467-020-14647-9","article-title":"Capsid protein structure in Zika virus reveals the flavivirus assembly process","volume":"11","author":"Tan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103581_b0595","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/ijms20061375","article-title":"The light and dark sides of virtual screening: what is there to know?","volume":"20","author":"Gimeno","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103581_b0600","article-title":"Modeling the expansion of virtual screening libraries","author":"Lyu","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2023.103581_b0605","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41596-021-00659-2","article-title":"Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking","volume":"17","author":"Gentile","year":"2022","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2023.103581_b0610","doi-asserted-by":"crossref","first-page":"bbab211","DOI":"10.1093\/bib\/bbab211","article-title":"A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2","volume":"22","author":"Wang","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2023.103581_b0615","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.3390\/ijms20143389","article-title":"Chemi-Net: a molecular graph convolutional network for accurate drug property prediction","volume":"20","author":"Liu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103581_b0620","doi-asserted-by":"crossref","first-page":"13664","DOI":"10.1039\/D1SC04444C","article-title":"Structure-based de novo drug design using 3D deep generative models","volume":"12","author":"Li","year":"2021","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2023.103581_b0625","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103581_b0630","doi-asserted-by":"crossref","first-page":"bbac147","DOI":"10.1093\/bib\/bbac147","article-title":"D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19","volume":"23","author":"Yang","year":"2022","journal-title":"Brief Bioinform"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:08:42Z","timestamp":1761224922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1359644623000971"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103581","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computer-aided drug design in seeking viral capsid modulators","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103581"}}